Eyeing an IPO, Fulcrum execs nail down an $80M round on the way to the clinic with their first gene-regulating drug
In the latest sign that there’s more and more money chasing good science, Fulcrum Therapeutics has grabbed an $80 million B round to back its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
